Biomarker market projected to reach $244 billion by 2035

The global biomarker market is projected to grow from $86.95 billion in 2025 to $244.08 billion by 2035, representing a compound annual growth rate (CAGR) of 12.15% between 2026 and 2035. This expansion is driven by increasing demand for precision medicine, early disease diagnosis, and more efficient drug discovery processes.

Key drivers include the rising prevalence of cancer, cardiovascular diseases, and neurological disorders. Technological advancements in genomics, proteomics, and metabolomics, combined with artificial intelligence and machine learning, are enhancing the ability to identify disease-related patterns and develop high-precision diagnostic indicators. The shift toward personalized treatment approaches, supported by liquid biopsies and molecular diagnostics, further fuels market demand.

While growth is robust, challenges remain regarding the demonstration of clinical utility and navigating complex regulatory and reimbursement landscapes, such as the IVDR in Europe and insurance evaluation systems in the United States. North America is expected to lead the market in 2025 due to advanced medical infrastructure and significant investment in biotechnology research.